Mon, Apr 21, 2014, 1:03 AM EDT - U.S. Markets open in 8 hrs 27 mins


% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

newyorksalute 3 posts  |  Last Activity: Feb 25, 2014 2:13 PM Member since: Jan 28, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Phase III trials

    by petkary Feb 13, 2014 1:24 AM
    newyorksalute newyorksalute Feb 25, 2014 2:13 PM Flag

    the purchases were too large to be a 'smoke and mirrors' purchase. Insiders sell for numerous reasons, but they only buy for 1 reason; to make money. I didn't get on the IPO, but took a position at 10.25. Will likely be ups and downs for sure. Bios have come a long way in the past 6 months - this stock may drop in sympathy with others.

    Sentiment: Buy

  • Reply to

    should I buy this or Exxon?

    by opele1 Dec 31, 2013 12:22 PM
    newyorksalute newyorksalute Feb 5, 2014 4:25 PM Flag

    MRO for sure medium to long term. Much more nimble than XON. Good entry point?! under $32 is a very solid entry - I bought too soon at $33.5, but plan on holding for minimum of 3 months.

    Sentiment: Buy

  • Reply to

    why decline in price??

    by realfoxiegirl Feb 4, 2014 2:51 PM
    newyorksalute newyorksalute Feb 4, 2014 9:51 PM Flag

    There are some short term headwinds including a slow economy and over busy rail system. There are concerns about shipping oil by rail, which some fear may put more restraints on getting oil out of the bakken. These rail bottlenecks may become restraints in 2014 - can't keep ramping up production without a way to get the oil out. Long term outlook looks good - I do need to look at the full guidance for 2014 but I believe it is short term worries driving down the price.....will buy more if it drops again.

    Sentiment: Buy

13.65+0.15(+1.11%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.